For the past 16 years, Dr. Mathew has worked to unravel the molecular mechanisms that drive prostate cancer. Now, he and his research team have introduced an innovative therapy that reprograms prostate cancer cells, stripping them of their ability to hide from the body’s immune system and making them vulnerable to natural immune responses.
This new treatment has the potential to treat other cancers, including breast, ovarian and pancreatic. If the safety and efficacy of this therapy is confirmed in future clinical trials, it has the potential to significantly change the way oncologists look at cancer biology and the treatment of cancer.
This breakthrough study was recently selected as the “Editor’s Choice” to be highlighted in Molecular Cancer Research, a major endorsement of Dr. Mathew and his team’s work.
Dr. Mathew’s research is supported in part by Tufts Medical Center’s Prostate Cancer Research Fund, which has raised nearly $1.5 million to help incredible scientists like Dr. Mathew and his team advance knowledge and pioneer new discoveries.
